|Awarded On||August 24, 2018|
|Title||Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor-Positive Breast Cancer Refractory to Standard Therapy|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Kelly Hunt|
Approximately 266,120 new cases of invasive breast cancer and 40,920 deaths due to breast cancer are expected to occur in 2018. Recent advances in gene expression profiling have revealed multiple breast cancer subtypes with differing outcomes. The majority of the newly diagnosed breast cancers are hormone receptor-positive and HER2-negative. Among the estimated 3.5 million men and women in the US with a history of breast cancer, 20-30% of these individuals experience a recurrence of their breast cancer and thus, represents a tremendous problem for patients and clinicians. The risk of recurrence in HR+ cases is typically lower over the first 5-10 years using conventional adjuvant systemic the...